Ventus Therapeutics Competitors and Similar CompaniesClear all

Ventus Therapeutics's competitors and similar companies include DeNovaMed, Tikomed, Sanofi and Corestem.

	Ventus Therapeutics Ventus Therapeutics is a company that develops small molecule therapeutics intended to target key innate immune pathways.	DeNovaMed DeNovaMed is a pharmaceutical company specializing in therapeutic approaches to combat bacterial infections.	Tikomed Tikomed is a company that develops treatments for patients with severe and life-threatening conditions.	Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.	Corestem Corestem (코아스템) is a biopharmaceutical company that researches and commercializes stem cell technology.
Founding Date	Founding Date N/A	Founding Date 2006	Founding Date 2002	Founding Date 1994	Founding Date 2003
Type	Type Private	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy
Locations	Locations Montréal, CA HQ Waltham, US	Locations Halifax, CA HQ Toronto, CA	Locations Viken, SE HQ	Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more	Locations Seongnam-si, KR HQ
Employees	Employees 952% increase	Employees 6	Employees 8	Employees 82,878	Employees 354
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €45.4b (FY, 2025)	Revenue (est.) ₩28.8b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods €11.6b (FY, 2025)	Cost of goods ₩25.6b (FY, 2024)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit €37.6b (FY, 2025)	Gross profit ₩5.6b (FY, 2024)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income €8b (FY, 2025)	Net income (₩26.3b) (FY, 2024)
Funding
Latest funding round	Latest funding round $ 100m (about 5 years ago)	Latest funding round $ 500k (about 14 years ago)	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 160m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 310m	Total funding raised N/A